Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoMix 30 TID vs BID in T2DM Inadequately Controlled with Basal Insulin
NCT02582242Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 24 weeks. Started Oct 2015; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02582242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582242.